Home
 /
Papers
 /
Molecular Biology
 /
Dosage sensitivity of the loop extrusion rate confers tunability to genome folding while creating vulnerability to genetic disruption
Preprint
Open access
V1
Top 1% · Validated by QED

Dosage sensitivity of the loop extrusion rate confers tunability to genome folding while creating vulnerability to…

Rini Shah, Maxime M. C. Tortora, Nessim Louafi +7 more
September 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.08.14.667581
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Molecular Biology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

This work establishes loop extrusion rate as a tunable cellular parameter controlled by NIPBL/PDS5 dosage, resolving the mechanistic basis of Cornelia de Lange syndrome haploinsufficiency and revealing that opposing kinetic changes actively buffer chromosome architecture.

QED claims analysis

Summary

The rate of cohesin loop extrusion is a tunable biophysical parameter in cells, quantitatively controlled by the opposing dosages of NIPBL and PDS5 cofactors, which enables cells to buffer chromosome architecture by offsetting changes in cohesin lifetime while creating exquisite dosage sensitivity that explains the haploinsufficiency observed in Cornelia de Lange syndrome.

See full analysis
Main Claim 1 –

NIPBL Modulates Cohesin Extrusion Rate Beyond Loading

Supporting evidence

  • Simulations Infer NIPBL Depletion Lowers Extrusion Rate to 40–50%
Main Claim 2 –

NIPBL Slows Extrusion to Offset WAPL-Increased Cohesin Lifetime

Main Claim 3 –

NIPBL:PDS5 Balance Tunes Cohesin Extrusion Rate and Folding

Supporting evidence

  • PDS5 Depletion Increases Extrusion Rate and Lifetime, Parsed by Compartments
  • Microscopy Confirms PDS5 Depletion Accelerates Extrusion and Vermicelli
  • Loop Extrusion Kinetics Changes Track Global Transcriptional States
  • NIPBL Overexpression Induces Vermicelli, Supporting NIPBL–PDS5 Competition
Main Claim 4 –

Cohesin Extrusion Rate Scales with NIPBL Dosage in Cells

Abstract

Genome folding is not static, but emerges from dynamic processes that control transcription, replication, recombination, and repair. DNA loop extrusion by cohesin is central to genome organization, yet it remains unclear how cells can tune extrusion kinetics to achieve precise and functional chromosome folding patterns. Here we discover extrusion rate acts as a tunable biophysical parameter in cells, quantitatively dialed by the respective dosage of the cohesin cofactors NIPBL and PDS5. Modulation of extrusion rate can offset changes in cohesin lifetime to buffer steady-state chromosome structure and transcriptional states, even in the face of abnormal extrusion dynamics. These findings provide a long-sought mechanistic basis for the genetic interactions between cohesin cofactors and the molecular origin of haploinsufficiency in cohesinopathies, such as Cornelia de Lange syndrome.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?